Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
Authors
Keywords
Recurrent, Malignant gliomas, Vorinostat, Bevacizumab, Temozolomide
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 137, Issue 2, Pages 349-356
Publisher
Springer Nature
Online
2017-12-21
DOI
10.1007/s11060-017-2724-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
- (2017) Sith Sathornsumetee et al. NEURO-ONCOLOGY
- MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
- (2015) M. Weller et al. CLINICAL CANCER RESEARCH
- Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways
- (2015) Valerie B. Sampson et al. PLoS One
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
- (2013) E. Galanis et al. CLINICAL CANCER RESEARCH
- Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)
- (2013) Riccardo Soffietti et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
- (2012) E. Q. Lee et al. CLINICAL CANCER RESEARCH
- Standards of care for treatment of recurrent glioblastoma—are we there yet?
- (2012) Michael Weller et al. NEURO-ONCOLOGY
- Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275
- (2011) Annette Bangert et al. ANTI-CANCER DRUGS
- Bevacizumab and daily temozolomide for recurrent glioblastoma
- (2011) Annick Desjardins et al. CANCER
- Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
- (2011) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Glioblastoma survival in the United States before and during the temozolomide era
- (2011) Derek R. Johnson et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
- (2011) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
- (2010) J. J. C. Verhoeff et al. ANNALS OF ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines
- (2010) Bhaswati Sarcar et al. JOURNAL OF NEURO-ONCOLOGY
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells
- (2009) Maiko Suzuki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat in solid and hematologic malignancies
- (2009) David Siegel et al. Journal of Hematology & Oncology
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More